Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022)

Revolution Medicines (RVMD) has 4 years of Non-Current Deffered Revenue data on record, last reported at $5.4 million in Q3 2022.

  • For Q3 2022, Non-Current Deffered Revenue fell 44.02% year-over-year to $5.4 million; the TTM value through Sep 2022 reached $5.4 million, down 44.02%, while the annual FY2021 figure was $6.6 million, 22.5% down from the prior year.
  • Non-Current Deffered Revenue reached $5.4 million in Q3 2022 per RVMD's latest filing, up from $3.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $12.4 million in Q1 2020 and bottomed at $1.7 million in Q4 2019.
  • Average Non-Current Deffered Revenue over 4 years is $7.6 million, with a median of $7.9 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 387.13% in 2020, then crashed 49.65% in 2022.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $1.7 million in 2019, then soared by 387.13% to $8.5 million in 2020, then dropped by 22.5% to $6.6 million in 2021, then dropped by 17.57% to $5.4 million in 2022.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $5.4 million in Q3 2022, $3.8 million in Q2 2022, and $5.7 million in Q1 2022.